BYOMass is a preclinical pharmaceutical company focused on developing innovative biologic and small molecule drugs that target specific members of the TGF-β superfamily. This superfamily consists of over 30 secreted factors that play crucial roles in various physiological processes, including tissue repair, immunoregulation, and reproductive function. Dysregulation of these proteins is linked to numerous diseases, such as inflammation and cancer. BYOMass aims to selectively modulate these pathways rather than directly inhibiting TGF-β, which can pose safety risks. Their approach emphasizes precision medicine, utilizing plasma biomarkers to stratify patients and ensure effective dosing, thereby enhancing the therapeutic index of their candidates.

The company is building a robust pipeline of therapeutics designed to address both orphan and common diseases with high unmet medical needs. Their strategy includes developing first-in-class small molecules and biologics that are engineered for safety and efficacy. BYOMass's leadership team, composed of experienced professionals from large pharmaceutical backgrounds, is committed to translating their drug discovery projects into viable clinical programs. By focusing on innovative clinical development plans, they aim to deliver early signs of efficacy in Phase 1 trials efficiently, ultimately transforming patient lives through their targeted therapeutic solutions.

United States

BYOMass is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need. Selectively targeting specific members and pathways within the TGF-β superfamily has the potential to be a meaningful class of therapeutics within oncology, inflammatory/immune, fibrotic, and metabolic diseases.

BYOMass

Company Details